Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1055

1.

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.

Saiki M, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Nishio M.

Lung Cancer. 2019 Jul;133:4-9. doi: 10.1016/j.lungcan.2019.04.022. Epub 2019 Apr 27.

PMID:
31200826
2.

Musculoskeletal Ultrasound Scanning Protocol Consensus Statements on Scanning Conventions and Documentation in the U.S.

Torralba KD, Choi KS, Salto LM, Fairchild R, Cannella AC, Kissin EY, Thiele R, Evangelisto A, Nishio MJ; Ultrasound School of North American Rheumatologists (USSONAR).

Arthritis Care Res (Hoboken). 2019 Jun 14. doi: 10.1002/acr.24005. [Epub ahead of print]

PMID:
31199596
3.

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.

Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J.

Eur J Cancer. 2019 Jun 10;116:137-147. doi: 10.1016/j.ejca.2019.05.008. [Epub ahead of print]

4.

In vitro bone-like nodules generated from patient-derived iPSCs recapitulate pathological bone phenotypes.

Kawai S, Yoshitomi H, Sunaga J, Alev C, Nagata S, Nishio M, Hada M, Koyama Y, Uemura M, Sekiguchi K, Maekawa H, Ikeya M, Tamaki S, Jin Y, Harada Y, Fukiage K, Adachi T, Matsuda S, Toguchida J.

Nat Biomed Eng. 2019 Jun 10. doi: 10.1038/s41551-019-0410-7. [Epub ahead of print]

PMID:
31182836
5.

Profilin2 is required for filamentous actin formation induced by human parainfluenza virus type 2.

Ohta K, Matsumoto Y, Nishio M.

Virology. 2019 May 24;533:108-114. doi: 10.1016/j.virol.2019.05.013. [Epub ahead of print]

PMID:
31150988
6.

Bayesian Statistical Model of Item Response Theory in Observer Studies of Radiologists.

Nishio M, Akasaka T, Sakamoto R, Togashi K.

Acad Radiol. 2019 May 27. pii: S1076-6332(19)30231-4. doi: 10.1016/j.acra.2019.04.014. [Epub ahead of print]

PMID:
31147237
7.

A complementary scheme for automated detection of high-uptake regions on dedicated breast PET and whole-body PET/CT.

Minoura N, Teramoto A, Ito A, Yamamuro O, Nishio M, Saito K, Fujita H.

Radiol Phys Technol. 2019 May 25. doi: 10.1007/s12194-019-00516-8. [Epub ahead of print]

PMID:
31129787
8.

MOB1 regulates thymocyte egress and T cell survival in mice in a YAP1-independent manner.

Kato W, Nishio M, To Y, Togashi H, Mak TW, Takada H, Ohga S, Maehama T, Suzuki A.

Genes Cells. 2019 May 24. doi: 10.1111/gtc.12704. [Epub ahead of print]

PMID:
31125466
9.

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.

Kawashima Y, Nishikawa S, Ninomiya H, Yoshida R, Takano N, Oguri T, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ishikawa Y, Nishio M.

Intern Med. 2019;58(10):1479-1484. doi: 10.2169/internalmedicine.1673-18. Epub 2019 May 15.

10.

Chronological Change of Vascular Reactivity to cGMP Generators in the Balloon-Injured Rat Carotid Artery.

Tawa M, Shimosato T, Sakonjo H, Masuoka T, Nishio M, Ishibashi T, Okamura T.

J Vasc Res. 2019 May 14:1-8. doi: 10.1159/000498896. [Epub ahead of print]

PMID:
31085923
11.

Predicting postpartum cardiac events in pregnant women with complete atrioventricular block.

Nakashima A, Miyoshi T, Aoki-Kamiya C, Nishio M, Horiuchi C, Tsuritani M, Iwanaga N, Katsuragi S, Neki R, Ikeda T, Yoshimatsu J.

J Cardiol. 2019 May 3. pii: S0914-5087(19)30099-1. doi: 10.1016/j.jjcc.2019.04.002. [Epub ahead of print]

PMID:
31060956
12.

Importance of tyrosine in the RNA-binding domain of human parainfluenza virus type 2 nucleoprotein for polymerase activity.

Matsumoto Y, Ohta K, Nishio M.

Arch Virol. 2019 Jul;164(7):1851-1855. doi: 10.1007/s00705-019-04240-x. Epub 2019 May 4.

PMID:
31055651
13.

Responsiveness of rat aorta and pulmonary artery to cGMP generators in the presence of thiol or heme oxidant.

Tawa M, Yamashita Y, Masuoka T, Nakano K, Yoshida J, Nishio M, Ishibashi T.

J Pharmacol Sci. 2019 Apr 16. pii: S1347-8613(19)30038-6. doi: 10.1016/j.jphs.2019.04.002. [Epub ahead of print]

14.

Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].

Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T.

Lung Cancer. 2019 Jun;132:160. doi: 10.1016/j.lungcan.2019.04.012. Epub 2019 Apr 24. No abstract available.

15.

Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.

Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M.

Lung Cancer. 2019 May;131:69-77. doi: 10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21.

PMID:
31027701
16.

Exogenous Cytokine-Free Differentiation of Human Pluripotent Stem Cells into Classical Brown Adipocytes.

Oka M, Kobayashi N, Matsumura K, Nishio M, Saeki K.

Cells. 2019 Apr 24;8(4). pii: E373. doi: 10.3390/cells8040373.

17.

Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet's Disease.

Kinoshita H, Nishioka H, Ikeda A, Ikoma K, Sameshima Y, Ohi H, Tatsuno M, Kouyama J, Kawamoto C, Mitsui T, Tamura Y, Hashimoto Y, Nishio M, Ogashiwa T, Saigusa Y, Maeda S, Kimura H, Kunisaki R, Koike K.

J Gastroenterol Hepatol. 2019 Apr 24. doi: 10.1111/jgh.14690. [Epub ahead of print]

PMID:
31017728
18.

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20. No abstract available.

19.

Peritoneal inclusion cysts treated with a levonorgestrel-releasing intrauterine system: A case report.

Tamai H, Kinugasa M, Nishio M, Miyake M.

Case Rep Womens Health. 2019 Mar 28;22:e00113. doi: 10.1016/j.crwh.2019.e00113. eCollection 2019 Apr.

20.

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.

Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Sukigara T, Nakamura K, Kuchiba A, Ohe Y.

Eur J Cancer. 2019 May;113:78-86. doi: 10.1016/j.ejca.2019.03.012. Epub 2019 Apr 13.

21.

Novel regulatory systems for acetylcholine release in rat striatum and anti-Alzheimer's disease drugs.

Muramatsu I, Uwada J, Yoshiki H, Sada K, Lee KS, Yazawa T, Taniguchi T, Nishio M, Ishibashi T, Masuoka T.

J Neurochem. 2019 Jun;149(5):605-623. doi: 10.1111/jnc.14701. Epub 2019 May 7.

PMID:
30968952
22.

Regulation of Hazara virus growth through apoptosis inhibition by viral nucleoprotein.

Matsumoto Y, Nouchi T, Ohta K, Nishio M.

Arch Virol. 2019 Jun;164(6):1597-1607. doi: 10.1007/s00705-019-04236-7. Epub 2019 Apr 4.

PMID:
30949813
23.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group.

Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.

PMID:
30922878
24.

CT temporal subtraction improves early detection of bone metastases compared to SPECT.

Onoue K, Nishio M, Yakami M, Aoyama G, Nakagomi K, Iizuka Y, Kubo T, Emoto Y, Akasaka T, Satoh K, Yamamoto H, Isoda H, Togashi K.

Eur Radiol. 2019 Mar 19. doi: 10.1007/s00330-019-06107-w. [Epub ahead of print]

PMID:
30888486
25.

TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X.

Ito K, Nishio M, Kato M, Murakami H, Aoyagi Y, Ohe Y, Okayama T, Hashimoto A, Ohsawa H, Tanaka G, Nonoshita K, Ito S, Matsuo K, Miyadera K.

Mol Cancer Ther. 2019 May;18(5):920-928. doi: 10.1158/1535-7163.MCT-18-0645. Epub 2019 Mar 14.

PMID:
30872380
26.

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R.

J Exp Med. 2019 Apr 1;216(4):982-1000. doi: 10.1084/jem.20180870. Epub 2019 Mar 14.

27.

Claudin-1 inhibits human parainfluenza virus type 2 dissemination.

Yumine N, Matsumoto Y, Ohta K, Fukasawa M, Nishio M.

Virology. 2019 May;531:93-99. doi: 10.1016/j.virol.2019.01.031. Epub 2019 Mar 6.

PMID:
30856486
28.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T.

Int J Clin Oncol. 2019 May;24(5):485-493. doi: 10.1007/s10147-019-01396-z. Epub 2019 Mar 4.

29.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16. Erratum in: Lung Cancer. 2019 Jun;132:157-158.

30.

Electrical and Structural Properties of the Partial Ternary Thin-Film System Ni-Si-B.

Wambach M, Nguyen N, Hamann S, Nishio M, Yagyu S, Chikyow T, Ludwig A.

ACS Comb Sci. 2019 Apr 8;21(4):310-315. doi: 10.1021/acscombsci.8b00175. Epub 2019 Mar 11.

PMID:
30790519
31.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.

Nishio M, Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T.

Invest New Drugs. 2019 Feb 21. doi: 10.1007/s10637-019-00732-4. [Epub ahead of print]

PMID:
30790152
32.

Antiosteoporotic Effects of Acer palmatum Extract on Osteoclastogenesis and Osteoblastogenesis.

Kuriya K, Nishio M, Wada S, Katsuzaki H, Nishise M, Okamoto H, Umekawa H.

J Med Food. 2019 Apr;22(4):365-373. doi: 10.1089/jmf.2018.4243. Epub 2019 Feb 20.

PMID:
30785809
33.

ANXA10 induction by interaction with tumor-associated macrophages promotes the growth of esophageal squamous cell carcinoma.

Kodaira H, Koma YI, Hosono M, Higashino N, Suemune K, Nishio M, Shigeoka M, Yokozaki H.

Pathol Int. 2019 Mar;69(3):135-147. doi: 10.1111/pin.12771. Epub 2019 Feb 13.

PMID:
30758105
34.

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.

Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.

Cancer Res. 2019 Apr 1;79(7):1658-1670. doi: 10.1158/0008-5472.CAN-18-2052. Epub 2019 Feb 8.

PMID:
30737231
35.

Rivaroxaban for Fully Occlusive Inferior Vena Cava Filter Thrombus.

Sakatani A, Nishio M, Kume K, Doi Y, Hirooka K.

Circ J. 2019 Feb 6. doi: 10.1253/circj.CJ-18-1141. [Epub ahead of print] No abstract available.

36.

MR Imaging Properties of ex vivo Common Marmoset Brain after Formaldehyde Fixation.

Haga Y, Hata J, Uematsu A, Seki F, Komaki Y, Mizumura M, Nishio M, Kaneko T, Kishi N, Okano H, Furukawa A.

Magn Reson Med Sci. 2019 Feb 7. doi: 10.2463/mrms.mp.2018-0086. [Epub ahead of print]

37.

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.

Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T.

Clin Lung Cancer. 2019 May;20(3):e317-e328. doi: 10.1016/j.cllc.2018.12.018. Epub 2018 Dec 31.

38.

Uptake of 18F-Fluorodeoxyglucose in Major Salivary Gland Cancer Predicts Survival Adjusting for Pathological Stage.

Suzuki H, Tamaki T, Nishio M, Terada H, Nishikawa D, Koide Y, Beppu S, Hanai N.

Anticancer Res. 2019 Feb;39(2):1043-1049. doi: 10.21873/anticanres.13211.

PMID:
30711993
39.

Augmentation of Endogenous Acetylcholine Uptake and Cholinergic Facilitation of Hippocampal Long-Term Potentiation by Acetylcholinesterase Inhibition.

Masuoka T, Uwada J, Kudo M, Yoshiki H, Yamashita Y, Taniguchi T, Nishio M, Ishibashi T, Muramatsu I.

Neuroscience. 2019 Apr 15;404:39-47. doi: 10.1016/j.neuroscience.2019.01.042. Epub 2019 Jan 30.

PMID:
30708046
40.

[A Case of a Patient with Multiple Liver Metastases of Colorectal Cancer with Relapse-Free, Long-Term Survival and Responding Completely to Chemotherapy after Primary Lesion Resection].

Nishio M, Sakai T, Mizutani T, Soga K, Koh T, Oguro A, Nakagawa N.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2279-2281. Japanese.

PMID:
30692437
41.

Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma.

Higashino N, Koma YI, Hosono M, Takase N, Okamoto M, Kodaira H, Nishio M, Shigeoka M, Kakeji Y, Yokozaki H.

Lab Invest. 2019 Jun;99(6):777-792. doi: 10.1038/s41374-018-0185-6. Epub 2019 Jan 25.

PMID:
30683902
42.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
43.

Estimation of lung cancer risk using homology-based emphysema quantification in patients with lung nodules.

Nishio M, Kubo T, Togashi K.

PLoS One. 2019 Jan 22;14(1):e0210720. doi: 10.1371/journal.pone.0210720. eCollection 2019.

44.

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Okada K, Araki M, Sakashita T, Ma B, Kanada R, Yanagitani N, Horiike A, Koike S, Oh-Hara T, Watanabe K, Tamai K, Maemondo M, Nishio M, Ishikawa T, Okuno Y, Fujita N, Katayama R.

EBioMedicine. 2019 Mar;41:105-119. doi: 10.1016/j.ebiom.2019.01.019. Epub 2019 Jan 17.

45.

Hippo pathway controls cell adhesion and context-dependent cell competition to influence skin engraftment efficiency.

Nishio M, Miyachi Y, Otani J, Tane S, Omori H, Ueda F, Togashi H, Sasaki T, Mak TW, Nakao K, Fujita Y, Nishina H, Maehama T, Suzuki A.

FASEB J. 2019 Apr;33(4):5548-5560. doi: 10.1096/fj.201802005R. Epub 2019 Jan 14.

PMID:
30640535
46.

A Minigenome Study of Hazara Nairovirus Genomic Promoters.

Matsumoto Y, Ohta K, Kolakofsky D, Nishio M.

J Virol. 2019 Mar 5;93(6). pii: e02118-18. doi: 10.1128/JVI.02118-18. Print 2019 Mar 15.

PMID:
30626667
47.

KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.

Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Han SR, Noguchi K, Shimamoto T, Kato T.

Cancer Sci. 2019 Mar;110(3):1012-1020. doi: 10.1111/cas.13932. Epub 2019 Feb 16.

48.

Nucleocytoplasmic shuttling of the human parainfluenza virus type 2 phosphoprotein.

Ohtsuka J, Matsumoto Y, Ohta K, Fukumura M, Tsurudome M, Nosaka T, Nishio M.

Virology. 2019 Feb;528:54-63. doi: 10.1016/j.virol.2018.12.005. Epub 2018 Dec 18.

PMID:
30576860
49.

First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.

Kishi K, Sakai H, Seto T, Kozuki T, Nishio M, Imamura F, Nokihara H, Satouchi M, Nakagawa S, Tahata T, Nakagawa K.

Cancer Treat Res Commun. 2019;18:100113. doi: 10.1016/j.ctarc.2018.10.004. Epub 2018 Oct 31.

50.

Cardiac metastasis in a living patient with oral cancer.

Fujio H, Otsuki N, Horichi Y, Yanagisawa S, Nishio M, Teshima M, Shinomiya H, Hashikawa K, Nibu KI.

Auris Nasus Larynx. 2018 Nov 20. pii: S0385-8146(18)30651-5. doi: 10.1016/j.anl.2018.10.018. [Epub ahead of print]

PMID:
30470634

Supplemental Content

Loading ...
Support Center